

DAFTAR PUSTAKA

- A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases—PubMed.* (n.d.). Retrieved February 1, 2024, from <https://pubmed.ncbi.nlm.nih.gov/31582227/>
- Aeddula, N. R., & Baradhi, K. M. (2024). Reflux nephropathy. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK526055/>
- Agarwal, A., & Nath, K. A. (2020). Pathophysiology of chronic kidney disease progression: Organ and Cellular Considerations. In *Chronic Renal Disease* (pp. 263–278). Elsevier. <https://doi.org/10.1016/B978-0-12-815876-0.00018-8>
- American Diabetes Association. (2010a). Standard of Medical Care in Diabetes (Position Statement). *Diabetes Care* 33: (Suppl.1), S11-S36.
- Barzilay, J. I., Farag, Y. M. K., & Durthaler, J. (2024). Albuminuria: An underappreciated risk factor for cardiovascular disease. *Journal of the American Heart Association*, 13(2), e030131. <https://doi.org/10.1161/JAHA.123.030131>
- Chapter 1: Definition and classification of CKD. (2013). *Kidney International Supplements*, 3(1), 19–62. <https://doi.org/10.1038/kisup.2012.64>
- Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic Kidney Disease diagnosis and management. *JAMA*, 322(13), 1294–1304. <https://doi.org/10.1001/jama.2019.14745>
- Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., Tobe, S. W., Tomson, C. R. V., & Mann, J. F. E. (2021). KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease.



Kidney International, 99(3), S1–S87.

<https://doi.org/10.1016/j.kint.2020.11.003>

Coresh, J., Astor, B. C., Greene, T., Eknoyan, G., & Levey, A. S. (2003). Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 41(1), 1–12. <https://doi.org/10.1053/ajkd.2003.50007>

Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehre G, et al. (2023) Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. *Crossmark*. 90;p. 648–657. Available from: <http://dx.doi.org/10.1016/j.kint.2016.04.024>

Garcia G, Iyengar A, Kaze F, et al. (2022) Sex and gender differences in chronic kidney disease and access to care around the globe. *Seminars in Nephrology*. 42(2);pp 101–113. Available from: <https://doi.org/10.1016/j.semnephrol.2022.04.0011>

Foundation NK. Frequently Asked Question about GFR Estimation.

Humphreys, B. D. (2018). Mechanisms of Renal Fibrosis. *Annual Review of Physiology*, 80, 309–326. <https://doi.org/10.1146/annurev-physiol-022516-034227>

Isakova, T., Xie, H., Yang, W., Xie, D., Anderson, A. H., Scialla, J., Wahl, P., Gutiérrez, O. M., Steigerwalt, S., He, J., Schwartz, S., Lo, J., Ojo, A., Sondheim, J., Hsu, C., Lash, J., Leonard, M., Kusek, J. W., Feldman, H. ... Chronic renal insufficiency cohort (CRIC) study group, for the. (2011). Fibroblast Growth Factor 23 and risks of mortality and end-stage renal



disease in patients with Chronic Kidney Disease. *JAMA*, 305(23), 2432–2439. <https://doi.org/10.1001/jama.2011.826>

KDIGO; 2024

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD - PubMed. (n.d.). Retrieved February 20, 2024, from <https://pubmed.ncbi.nlm.nih.gov/24647050/>

Kemendes RI. (2023). *PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA GINJAL KRONIK*.

Kemendes Kesehatan RI. (2018). *Hasil Riset Kesehatan Dasar (Riskesdas) 2018*. Badan Penelitian dan Pengembangan Kesehatan Kemendes RI. Jakarta.

Kendrick, J., Jovanovich, A., & Moe, S. (2019). Mineral Bone Disorders in Chronic Kidney Disease. In *Chronic Kidney Disease, Dialysis, and Transplantation* (pp. 145-161.e6). Elsevier. <https://doi.org/10.1016/B978-0-323-52978-5.00010-0>

Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: An update 2022. *Kidney International Supplements*, 12(1), 7–11. <https://doi.org/10.1016/j.kisu.2021.11.003>

Kshirsagar, A. V., Bang, H., Bombardieri, A. S., Vupputuri, S., Shoham, D. A., Kern, L. M., Klemmer, P. J., Mazumdar, M., & August, P. A. (2008). A simple algorithm to predict incident kidney disease. *Archives of Internal Medicine*, 168(22), 2466–2473. <https://doi.org/10.1001/archinte.168.22.2466>

Lambert Heerspink, H. J., & Gansevoort, R. T. (2015). Albuminuria Is an appropriate Therapeutic Target in Patients with CKD: The Pro View. *Clinical Journal of the American Society of Nephrology : CJASN*, 10(6), 1079–1088. <https://doi.org/10.2215/CJN.11511114>



Leifheit-Nestler, M., & Haffner, D. (2021). How FGF23 shapes multiple organs in chronic kidney disease. *Molecular and Cellular Pediatrics*, 8(1), 12. <https://doi.org/10.1186/s40348-021-00123-x>

Lewandowski MJ, Krenn S, Kurnikowski A, Bretschneider P, et al. (2023) Chronic kidney disease is more prevalent among women but more men than women are under nephrological care. *Wien Klin Wochenschr.* 135:pp. 89–96. Available from: <https://doi.org/10.1007/s00508-022-02074-3>

Martin, A., David, V., & Quarles, L. D. (2012). Regulation and Function of the FGF23/Klotho Endocrine Pathways. *Physiological Reviews*, 92(1), 131–155. <https://doi.org/10.1152/physrev.00002.20>

Mateos R, Doladé N, García CA, Diaz JM, Ibarz, M, et al. (2022) The Increase in FGF23 Induced by Calcium Is Partially Dependent on Vitamin D Signaling. *Nutrients*.14: p.2576. Available from: <https://doi.org/10.3390/nu14132576>

Merchant A, Ling E. (2023) An approach to treating older adults with chronic kidney disease. *CMAJ.* 1;195:E612-8. Available from: doi. 10.1503/cmaj.221427

Murton, M., Goff-Leggett, D., Bobrowska, A., Garcia Sanchez, J. J., James, G., Wittbrodt, E., Nolan, S., Sörstadius, E., Pecoits-Filho, R., & Tuttle, K. (2021). Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review. *Advances in Therapy*, 38(1), 180–200. <https://doi.org/10.1007/s12325-020-01568-8>

MyBioSource (2021). Fibroblast Growth Factor 23-Elisa Kit Analyze

National Kidney Foundation. (2002). K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 39(2 Suppl 1), S1-266.



- Pasternak, M., Liu, P., Quinn, R., Elliott, M., Harrison, T. G., Hemmelgarn, B., Lam, N., Ronksley, P., Tonelli, M., & Ravani, P. (2022). Association of Albuminuria and Regression of Chronic Kidney Disease in Adults With Newly Diagnosed Moderate to Severe Chronic Kidney Disease. *JAMA Network Open*, 5(8), e2225821. <https://doi.org/10.1001/jamanetworkopen.2022.25821>
- Pavik, I., Jaeger, P., Kistler, A. D., Poster, D., Krauer, F., Cavelti-Weder, C., Rentsch, K. M., Wüthrich, R. P., & Serra, A. L. (2011). Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. *Kidney International*, 79(2), 234–240. <https://doi.org/10.1038/ki.2010.375>
- Rahmawati F. Aspek Laboratorium Gagal Ginjal Kronik. *J Ilm Kedokt Wijaya Kusuma*. 2018;6(1):14.
- Raja, P., Maxwell, A. P., & Brazil, D. P. (2021). The Potential of Albuminuria as a Biomarker of Diabetic Complications. *Cardiovascular Drugs and Therapy*, 35(3), 455–466. <https://doi.org/10.1007/s10557-020-07035-4>
- Ren, J., & Dai, C. (2020). Pathophysiology of Chronic Kidney Disease. In J. Yang & W. He (Eds.), *Chronic Kidney Disease* (pp. 13–32). Springer Singapore. https://doi.org/10.1007/978-981-32-9131-7_2
- Ren F, Li M, Xu H, Qin X, Teng Y. (2021). Urin albumin-to-creatinine ratio within the normal range and risk of hypertension in the general population: A meta-analysis. *J Clin Hypertens (Greenwich)*. 23(7):1284-1260.
- Sapra, A., & Bhandari, P. (2023). Diabetes. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK551501/>



I Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017). Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic

kidney disease patients? A narrative review. *Journal of Advanced Research*, 8(3), 271–278. <https://doi.org/10.1016/j.jare.2017.02.003>

Singh, S., Grabner, A., Yanucil, C., Schramm, K., Czaya, B., Krick, S., Czaja, M. J., Bartz, R., Abraham, R., Di Marco, G. S., Brand, M., Wolf, M., & Faul, C. (2016). Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. *Kidney International*, 90(5), 985–996. <https://doi.org/10.1016/j.kint.2016.05.019>

Sun P, Ming X, Song T, Chen Y, Yang X, Sun Z, Zheng X, Tong L, Ma Z and Wan Z (2024) Global burden of chronic kidney disease in adolescents and young adults, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Front. Endocrinol.* 15:1389342. Available from: doi.10.3389/fendo.2024.1389342

Sunderraj A , Wong M , Gutie´rrez OM , Wolf M, et al. (2023) Associations of FGF23 with 10-Year Change in eGFR and UACR and with Incident CKD in the CARDIA Cohort. *KIDNEY*. 360(4): pp.1236–1244.

Tojo, A. (2013). The role of the kidney in protein metabolism: The capacity of tubular lysosomal proteolysis in nephrotic syndrome. *Kidney International*, 84(5), 861–863. <https://doi.org/10.1038/ki.2013.284>

Vaidya, S. R., & Aeddula, N. R. (2024). Chronic Kidney Disease. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK535404/>

Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017). Chronic Kidney Disease. *Lancet (London, England)*, 389(10075), 1238–1252. [https://doi.org/10.1016/S0140-6736\(16\)32064-5](https://doi.org/10.1016/S0140-6736(16)32064-5)

Wilson S., Mone, P., Jankauskas, S. S., Gambardella, J., & Santulli, G. (2021). Chronic kidney disease: Definition, updated epidemiology, staging, and



mechanisms of increased cardiovascular risk. *The Journal of Clinical Hypertension*, 23(4), 831–834. <https://doi.org/10.1111/jch.14186>

Yang, J., & He, W. (Eds.). (2020). *Chronic Kidney Disease: Diagnosis and Treatment*. Springer Singapore. <https://doi.org/10.1007/978-981-32-9131-7>



Optimized using
trial version
www.balesio.com